As Isomorphic Labs goals its synthetic intelligence instruments at drug growth, it’s organising a brand new outpost within the biotech hub of Cambridge.
Based in 2021 as a derivative of Alphabet AI firm DeepMind, Isomorphic constructed off the protein structure-predicting energy of the deep studying mannequin AlphaFold. “Our core thesis was, and is, that we will use AI to essentially remodel and reimagine how we uncover medication,” mentioned Isomorphic President Colin Murdoch.
After growing AlphaFold right into a drug design platform, the corporate has entered the period the place it’s progressing a few of these AI-enabled drug candidates towards medical trials — and to try this, it wants a footprint in the US.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
